NCT04962906View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes

PHASE2CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

July 5, 2021

Primary Completion Date

August 5, 2021

Study Completion Date

August 15, 2021

Conditions
COVID-19 Vaccines
Interventions
DRUG

Gam-COVID-Vac / Gam-COVID-Vac

A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.

Trial Locations (1)

1284

Ministerio de Salud de la Ciudad Autónoma de Buenos Aires, Buenos Aires

All Listed Sponsors
lead

Ministerio de Salud de Ciudad Autónoma de Buenos Aires

OTHER_GOV